<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583866</url>
  </required_header>
  <id_info>
    <org_study_id>1148277</org_study_id>
    <secondary_id>5P01HL069999</secondary_id>
    <nct_id>NCT03583866</nct_id>
  </id_info>
  <brief_title>Adiposity and Endothelin Receptor Function</brief_title>
  <acronym>END-RF</acronym>
  <official_title>Adiposity and Endothelin Receptor Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elevated levels of ET-1 have been implicated in cardiovascular disease and some forms of
      hypertension. Due to the strong, positive correlation between obesity and hypertension, the
      present study will explore the contribution of adiposity in ETB receptor function and aim to
      elucidate if ETB receptor dysfunction is a major contributor to hypertension in obesity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is designed to investigate the influence of adiposity on ETB receptor
      function and subsequent vascular responses. The combination of ET-1, ET-3, and the respective
      ETA and ETB receptor antagonists will be used to provide insight into the mechanisms of ETB
      receptor dysfunction in the presence of adiposity. Previous studies have revealed elevations
      in circulating ET-1 in obese individuals; therefore, we predict that obese subjects will
      exhibit 1) ETB receptor dysfuncton compared to lean subjects and 2) an improvement in ETB
      receptor dysfunction following treatment with Candesartan.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in Flow-Mediated Dilation (FMD)</measure>
    <time_frame>pre-treatment Baseline and 7 days post-treatment</time_frame>
    <description>Change in Brachial artery FMD induced by reactive hyperemia assessed vascular endothelial function at baseline and several hours after treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Candesartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sub chronic (7 days) Candesartan (16 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Endothelial function will be determined following a seven day treatment of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <description>7 days of Candesartan (16mg/day)</description>
    <arm_group_label>Candesartan</arm_group_label>
    <other_name>Blopress, Atacand, Amias, and Ratacand</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>7 days of Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Lactose capsule, Maltose capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢ If you are an adult between the ages of 18-40 year old

        Exclusion Criteria:

          -  Evidence of cardiovascular, pulmonary, renal, hepatic, cerebral, or metabolic disease

          -  Evidence of pregnancy

          -  Using medications that affect vascular tone (i.e., nitrates, etc.)

          -  Use of any anticoagulants (i.e. aspirin)

          -  Anemia

          -  If you are postmenopausal

          -  If you have uncontrolled hypertension (treated resting SBP &gt;140 mm Hg or DBP &gt;90 mm
             Hg)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Harris, PHD, CES</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augusta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ryan Harris, PhD, CES</last_name>
    <phone>706-721-5998</phone>
    <email>ryharris@augusta.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacob Looney, BS</last_name>
    <phone>706-721-5483</phone>
    <email>jlooney@augusta.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Looney, BS</last_name>
      <phone>706-721-5483</phone>
      <email>jlooney@augusta.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://facebook.com/harrislab</url>
    <description>Laboratory of Integrative and Exercise Physiology Website</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 27, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Ryan Harris</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>blood pressure</keyword>
  <keyword>microdialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

